AMGN · Amgen Inc.
$358.332026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$328
-8.4% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($328 · $640) Analysts Range ($185 · $427) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $28.2B | — | 34.4% | 13.4% | $8.4B | −$25.7B | −$17.3B | 6.4% | — | 11.7% | $71.8B | $12.35 | — |
| 2024.Q4 | $28.2B | 0.0% | 34.4% | 11.3% | $8.6B | $5.0B | $13.6B | 6.7% | — | 12.4% | $66.5B | $12.35 | — |
| 2025.Q1 | $33.4B | 18.6% | 26.6% | 10.8% | $7.9B | $4.1B | $12.0B | 6.7% | — | 11.6% | $70.3B | $7.52 | — |
| 2025.Q4 | $33.4B | 0.0% | 26.6% | 14.1% | $7.7B | −$1.0B | $6.6B | 6.2% | — | 10.9% | $69.7B | $7.52 | — |
| 2026.Q1 | $37.2B | 11.4% | 38.8% | 14.2% | $12.4B | −$1.9B | $10.5B | 6.2% | — | 17.4% | $72.7B | $14.34 | 13.5 |
| italics below = DCF projection · 10yr Rev CAGR: 3.5% |
| 2027.Q1 | $38.0B | +2.0% | 36.0% | 14.8% | $11.7B | −$780MM | $10.9B | 6.4% | $10.2B | 16.0% | $73.4B | $17.49 | 20.5 |
| 2028.Q1 | $39.0B | +2.6% | 37.0% | 15.3% | $12.2B | −$1.2B | $11.0B | 6.6% | $9.7B | 16.5% | $74.6B | $18.32 | 19.6 |
| 2029.Q1 | $40.0B | +2.7% | 38.9% | 15.9% | $13.1B | −$1.6B | $11.5B | 6.8% | $9.5B | 17.4% | $76.2B | $19.62 | 18.3 |
| 2030.Q1 | $41.4B | +3.5% | 39.1% | 16.5% | $13.5B | $0MM | $13.5B | 7.1% | $10.4B | 17.8% | $76.2B | $20.29 | 17.7 |
| 2031.Q1 | $43.0B | +3.8% | 39.1% | 17.1% | $14.0B | $0MM | $14.0B | 7.3% | $10.0B | 18.3% | $76.2B | $20.92 | 17.1 |
|
| Term. Yr+ | $54.4B | 4.1% | 33.9% | 20.0% | $14.8B | −$3.5B | $11.2B | 8.6% | $122.5B | 17.2% | — | — | — |
Active scenario IV: $328 (-8.4% vs market)